Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12925214rdf:typepubmed:Citationlld:pubmed
pubmed-article:12925214lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C0042900lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C1522481lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C0281722lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C0041484lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C0385723lld:lifeskim
pubmed-article:12925214lifeskim:mentionsumls-concept:C1420066lld:lifeskim
pubmed-article:12925214pubmed:issue3lld:pubmed
pubmed-article:12925214pubmed:dateCreated2003-8-19lld:pubmed
pubmed-article:12925214pubmed:abstractTextVitiligo is a common depigmentation disorder thought to result from autoimmune destruction of melanocytes. Recent studies suggest a role for cell-mediated immune responses to melanocyte differentiation antigens, including gp100, MelanA/MART-1, and tyrosinase, in vitiligo pathogenesis. This study investigated T cell reactivity to MelanA/MART-1, tyrosinase, and gp100, in HLA-A2-positive patients with vitiligo. Melanocyte-specific T cell responses were measured ex vivo via enzyme-linked immunospot assay following stimulation with MelanA/MART-1, tyrosinase, and modified gp100 epitopes. Antigen-specific T lymphocyte reactivity to gp100 peptides was seen in 15 of 17 (88%) patients, with many demonstrating very high reactivity at levels comparable with those observed with common recall antigens. Reactivity to gp100 was noted to be associated with disease activity. Antigen-specific T lymphocyte reactivity to MelanA/MART-1 and tyrosinase peptides was not observed ex vivo in our patients, and only one patient demonstrated responses to MelanA/MART-1 and tyrosinase peptides following in vitro re-stimulation. Our findings implicate T cell reactivity to gp100 in patients with active disease and support the concept of an immunopathologic mechanism in vitiligo, in which cell-mediated responses to normal melanocyte antigens play a crucial part.lld:pubmed
pubmed-article:12925214pubmed:languageenglld:pubmed
pubmed-article:12925214pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:citationSubsetIMlld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925214pubmed:statusMEDLINElld:pubmed
pubmed-article:12925214pubmed:monthSeplld:pubmed
pubmed-article:12925214pubmed:issn0022-202Xlld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:BarberBrian...lld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:SpanerDavidDlld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:ShearNeil HNHlld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:SambharaSurya...lld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:Mandelcorn-Mo...lld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:YauEddyElld:pubmed
pubmed-article:12925214pubmed:authorpubmed-author:DeBenedetteMa...lld:pubmed
pubmed-article:12925214pubmed:issnTypePrintlld:pubmed
pubmed-article:12925214pubmed:volume121lld:pubmed
pubmed-article:12925214pubmed:ownerNLMlld:pubmed
pubmed-article:12925214pubmed:authorsCompleteYlld:pubmed
pubmed-article:12925214pubmed:pagination550-6lld:pubmed
pubmed-article:12925214pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:meshHeadingpubmed-meshheading:12925214...lld:pubmed
pubmed-article:12925214pubmed:year2003lld:pubmed
pubmed-article:12925214pubmed:articleTitleCytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.lld:pubmed
pubmed-article:12925214pubmed:affiliationDivision of Dermatology, Sunnybrook and Women's College Health Sciences Center, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.lld:pubmed
pubmed-article:12925214pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2315entrezgene:pubmedpubmed-article:12925214lld:entrezgene
entrez-gene:6490entrezgene:pubmedpubmed-article:12925214lld:entrezgene
entrez-gene:7299entrezgene:pubmedpubmed-article:12925214lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12925214lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12925214lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12925214lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925214lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925214lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925214lld:pubmed